摘要
目的比较卵巢正常反应人群(NOR)拮抗剂方案中单用高纯度尿促性素(HP-hMG)与重组人卵泡刺激素(rFSH)促排卵的临床结局。方法回顾性收集行NOR拮抗剂助孕的患者,根据拮抗剂方案中采用超促排卵药物的不同,分为HP-hMG组和rFSH组。统计两组患者基本信息、促排卵情况、实验室指标以及临床结局等指标。结果最终纳入614例NOR患者:HP-hMG组(n=216),rFSH组(n=398)。两组间hCG注射日P及LH水平差异无统计学意义,HP-hMG组hCG注射日E2水平显著降低(P<0.001);HP-hMG组生化妊娠率(69.23%vs 63.51%)以及临床妊娠率(66.67%vs 59.46%)较rFSH组有升高的趋势。HP-hMG组卵巢过度刺激综合征(OHSS)发生率(2.31%vs 3.02%)较rFSH组有降低趋势。结论对于NOR接受拮抗剂方案助孕的患者,与采用rFSH相比,单独使用HP-hMG能够获得同样较好的临床妊娠率,并在降低OHSS发生率方面具有一定优势。
Objective To compare the differences in clinical outcomes of ovulation induction with highly purified human menopausal gonadotropin(HP-hMG,Menopur)versus recombinant human follicle stimulating hormone(rFSH,Gonal-F)in normal ovarian responder patients treated with the GnRH-antagonist protocol.Methods Patients treated with the GnRH-antagonist protocol were retrospectively analyzed and divided by gonadotropin(Gn)usage into HP-hMG group and rFSH group.The basic characteristics,ovulation induction method,laboratory indexes,and clinical outcomes were compared between the two groups.Results A total of 614 normal ovarian responder patients were enrolled in the study,with 216 in the HP-hMG group and 398 in the rFSH group.There was no significant difference in P levels and LH levels on the hCG trigger day between the two groups.However,the E 2 levels on the hCG trigger day were significantly lower in the HP-hMG group(P<0.001).Moreover,the HP-hMG group had a higher biochemical pregnancy rate(69.23%vs 63.51%)and clinical pregnancy rate(66.67%vs 59.46%)compared to the rFSH group.The incidence of OHSS in the HP-hMG group(2.31%vs 3.02%)showed a decreasing trend compared to the rFSH group.Conclusion Compared to rFSH,HP-hMG offers distinct advantages in reducing the incidence of OHSS and improving pregnancy outcomes in normal ovarian responder patients undergoing pituitary suppression with the GnRH-antagonist protocol.
作者
徐千花
曹云霞
曾娟
Xu Qianhua;Cao Yunxia;Zeng Juan(Dept of Obstetrics and Gynecology,The First Affiliated Hospital of Anhui Medical University,Hefei 230032;NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract,Hefei 230032;Key Laboratory of Birth Health of Ministry of Education,Hefei 230032;Anhui Province Key Laboratory of Reproductive Health and Genetics,Hefei 230032;Anhui Provincial Engineering Technology Research Center for Biopreservation and Artificial Organs,Hefei 230032)
出处
《安徽医科大学学报》
CAS
北大核心
2024年第6期966-970,共5页
Acta Universitatis Medicinalis Anhui
基金
国家自然科学基金(编号:82301864)
生殖健康与遗传安徽省重点实验室开放课题基金(编号:RHG-2021-1)。
